LCC in French_Virtual Tumor Board - EFGR NSCLC (1)

In this episode of Lung Cancer Considered, host Dr. Narjust Florez conducts three mock molecular tumor boards with Dr. Misako Nagasaka and Dr. Biagio Ricciuti, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion addresses the question, “How do we get the right molecular answer, at the right time, for the right patient?” Guests: Misako Nagasaka, MD, PhD Associate Clinical Professor University of California, Irvine Biagio Ricciuti, MD, PhD Thoracic Medical Oncologist, Dana-Farber Cancer Institute Faculty, Harvard School of Medicine

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guest Dr. Sam Rosner examine controversies around antibody-drug conjugates (ADCs) live from the 2026 Targeted Therapies of Lung Cancer (TTLC) conference. Guest: Sam Rosner, MD Assistant Professor of Medicine, University of Maryland School of Medicine Thoracic Medical Oncologist, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Angela Botticella and Dr. Jean Yannis Perentes. The tumor board focuses on the management of resectable EGFR-mutant NSCLC. Guests: Angela Botticella, MD Radiational Oncologist Department of Radiation Oncology Gustave Roussy Jean Yannis Perentes, MD, PhD Professor and Chief, Department of Thoracic Surgery University Hospital of Lausanne CHUV

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice. Guests: Hina Khan, MD Thoracic Oncologist Assistant Professor of Medicine Warren Alpert Medical School, Brown University Corey Langer, MD, FACP Director, Thoracic Oncology, Abramson Cancer Center Professor of Medicine , Perelman School of Medicine University of Pennsylvania

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores the evolving landscape of emerging molecular targets in NSCLC with Dr. Kelsey Pan and Rajat Thawani, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion highlights rare oncogenic drivers with a focus on clinical evidence, resistance mechanisms and trial design. The episode also addresses biomarker testing, the role of next-generation sequencing and liquid biopsy, and what the next five years may hold for precision treatment strategies in NSCLC. Guests: Kelsey Pan, MD, MPH Assistant Professor of Medicine Department of Hematology & Oncology, Thoracic Medical Oncology Section Emory University Winship Cancer Institute Rajat Thawani, MD Assistant Professor of Medicine Division of Hematology and Oncology Knight Cancer Institute, OHSU

This episode of Lung Cancer Considered focuses on a case of a patient with extensive stage SCLC. SCLC is a highly lethal subtype of lung cancer, accounting for about 13% of new lung cancer diagnoses with high variability based on geography and socioeconomic factors. The standard treatment for ES-SCLC had been platinum + etoposide for several decades, but over the past 7 years, we have had several new paradigm shifts that have led to real survival gains. To discuss current state of the art management, Guests: Raffaele Califano, Consultant at the Christie and Professor of Medical Oncology at Manchester University in the United Kingdom. Dr. Jessica Menis, thoracic medical oncologist at University Hospital of Verona, in Verona, Italy

This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale. Host: Dr. Stephen Liu Guests: Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology. Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of Melbourne Dr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University

As part of IASLC’s ongoing series of Lung Cancer Considered podcasts in world languages, Dr. Molly Li moderates a discussion in Cantonese with two expert cardiothoracic surgeons, Dr. Ben Li, Professor from The First Affiliated Hospital of Guangzhou Medical University and, and Dr. Calvin Ng, Professor from the Chinese University of Hong Kong. The discussion: reviews surgical management of early-stage NSCLC, including VATS, and lobar versus sublobar resection; and explores novel technologies including endobronchial therapy and tubeless anesthesia. Host: Molly Li, MD Clinical Assistant Professor Department of Clinical Oncology, CUHK, Hong Kong Guests: Shuben Li, MD, PhD Professor, Department of Thoracic Surgery National Center for Respiratory Medicine The First Affiliated Hospital of Guangzhou Medical University Calvin S.H. Ng, BSc MBBS, MD Environmental Foundation Professor of Thoracic Surgery Department of Surgery The Chinese University of Hong Kong (CUHK)

This episode of Lung Cancer Considered examines how artificial intelligence is being incorporated into patient care and what the future holds for this emerging technology. We will be discussing: • Is AI the right move for oncology care? • What is the impact on patient care and our patient expert’s experience? • And how can we learn more about AI? Guest: Dr. Sandip Patel, is a professor of Medicine at UCSD and a nationally recognized leader in precision cancer medicine and innovation. He specializes in early-phase clinical trials and immunotherapy, with a focus on developing innovative treatments for patients with advanced lung cancer. Today, we’re excited to welcome him to the podcast to discuss the future of AI in cancer care, in general, and in thoracic oncology in particular.